Adriana Teixeira

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +5

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

Maria Teresa Petrucci, Pilar Giraldo, Paolo Corradini et al. · British Journal of Haematology · 2013 · 123 citations · Full text

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong et al. · The Lancet Oncology · 2011 · 108 citations

Hematological Malignancy, Lymphoid Neoplasia, Rituximab Versus Rituximab +6

Cerebellar thiol status and motor deficit after lactational exposure to methylmercury

Jeferson Luís Franco, Adriana Teixeira, Flávia Carla Meotti et al. · Environmental Research · 2006 · 101 citations

Cerebellar Thiol Status, Neuroanatomy, Physiology +9